Overview

This registry aims to evaluate the long-term prognosis and valve durability of transcatheter aortic valve replacement (TAVR) in a real-world setting. Baseline characteristics, procedural data, and clinical outcomes will be collected in a prospective and observational manner.

Eligibility

Inclusion Criteria:

        Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart
        team and are eligible for TAVR therapy.
        2. Patients who understand the purpose of this study, agree to participate in the trial and
        sign the informed consent form
          -  1. Patients with aortic stenosis or aortic valve insufficiency who were evaluated by
             the Heart team and underwent TAVR therapy
          -  2. Patients who understand the purpose of the study, agree to participate in the trial
             and sign the informed consent form
        Exclusion Criteria:
          -  1. Patients who cannot provide informed consent
          -  2. Patients who are participating in other clinical trials